Home › Follicular Lymphoma › Illinois
Follicular Lymphoma clinical trials in Illinois
14 studies for Follicular Lymphoma are looking for participants at sites in Illinois.
Cities in Illinois
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- The University of Chicago Medical Center (UCMC), Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Evanston
- Research Site, Peoria
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Sep 21, 2026 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06526793Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 18 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Ruth M. Rothstein CORE Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06651177A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Local Institution - 0240, Arlington Heights
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06911502The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.